Second Line Capital, LLC Viking Therapeutics, Inc. Transaction History
Second Line Capital, LLC
- $388 Billion
- Q1 2025
A detailed history of Second Line Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Second Line Capital, LLC holds 50,381 shares of VKTX stock, worth $1.91 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
50,381
Previous 49,511
1.76%
Holding current value
$1.91 Million
Previous $1.99 Billion
38.93%
% of portfolio
0.31%
Previous 0.54%
Shares
4 transactions
Others Institutions Holding VKTX
# of Institutions
456Shares Held
66MCall Options Held
8.28MPut Options Held
3.44M-
Vanguard Group Inc Valley Forge, PA10.2MShares$385 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$228 Million0.01% of portfolio
-
State Street Corp Boston, MA4.06MShares$154 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$118 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.12MShares$118 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.91B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...